Marinus H J van Oers

Summary

Affiliation: Academic Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma
    Patrick W B Derksen
    Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands
    Blood 99:1405-10. 2002
  2. ncbi request reprint Rituximab maintenance therapy: a step forward in follicular lymphoma
    Marinus H J van Oers
    Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Haematologica 92:826-33. 2007
  3. pmc Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA)
    Saskia K Klein
    Ann Hematol 86:917-8. 2007
  4. ncbi request reprint Rituximab maintenance in indolent lymphoma: indications and controversies
    Marinus H J van Oers
    Department of Hematology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Curr Oncol Rep 9:378-83. 2007
  5. pmc Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
    Marinus H J van Oers
    Department of Hematology, F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 28:2853-8. 2010
  6. doi request reprint Treatment strategies in advanced stage follicular lymphoma
    Marinus H J van Oers
    Department of Haematology, F4 224, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Best Pract Res Clin Haematol 24:187-201. 2011
  7. ncbi request reprint Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study
    M H J van Oers
    Department of Hematology, Academic Medical Centre Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Ann Hematol 81:553-7. 2002
  8. ncbi request reprint Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
    Marinus H J van Oers
    Department of Hematology F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood 108:3295-301. 2006
  9. doi request reprint BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
    Marinus H J van Oers
    Department of Hematology F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 28:2246-52. 2010
  10. ncbi request reprint Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation
    Ramon Arens
    Departments of Experimental Immunology and Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Immunol 174:5915-20. 2005

Detail Information

Publications51

  1. ncbi request reprint Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma
    Patrick W B Derksen
    Department of Pathology, Academic Medical Center, University of Amsterdam, The Netherlands
    Blood 99:1405-10. 2002
    ..These results identify syndecan-1 as a functional coreceptor for HGF that promotes HGF/Met signaling in MM cells, thus suggesting a novel function for syndecan-1 in MM tumorigenesis...
  2. ncbi request reprint Rituximab maintenance therapy: a step forward in follicular lymphoma
    Marinus H J van Oers
    Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Haematologica 92:826-33. 2007
    ..Also, rituximab maintenance may help patients feel they can control their disease, rather than passively waiting for relapse...
  3. pmc Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA)
    Saskia K Klein
    Ann Hematol 86:917-8. 2007
  4. ncbi request reprint Rituximab maintenance in indolent lymphoma: indications and controversies
    Marinus H J van Oers
    Department of Hematology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Curr Oncol Rep 9:378-83. 2007
    ..Current data indicate that rituximab maintenance can be safely administered for up to 2 years, although assessment of long-term safety requires longer follow-up...
  5. pmc Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
    Marinus H J van Oers
    Department of Hematology, F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 28:2853-8. 2010
    ..At that time, the median follow-up for the maintenance phase was 33 months. Now, we report the long-term outcome of maintenance treatment, with a median follow-up of 6 years...
  6. doi request reprint Treatment strategies in advanced stage follicular lymphoma
    Marinus H J van Oers
    Department of Haematology, F4 224, Academic Medical Centre, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Best Pract Res Clin Haematol 24:187-201. 2011
    ....
  7. ncbi request reprint Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study
    M H J van Oers
    Department of Hematology, Academic Medical Centre Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Ann Hematol 81:553-7. 2002
  8. ncbi request reprint Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
    Marinus H J van Oers
    Department of Hematology F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood 108:3295-301. 2006
    ..52; P = .011). This is the first trial showing that in relapsed/resistant FL rituximab maintenance considerably improves PFS not only after CHOP but also after R-CHOP induction...
  9. doi request reprint BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
    Marinus H J van Oers
    Department of Hematology F4 224, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    J Clin Oncol 28:2246-52. 2010
    ..Here, we studied whether BCL2/IgH major break point levels in PB/BM correlated with response rates/quality for the induction phase and PFS for the maintenance phase...
  10. ncbi request reprint Cutting edge: CD95 maintains effector T cell homeostasis in chronic immune activation
    Ramon Arens
    Departments of Experimental Immunology and Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Immunol 174:5915-20. 2005
    ..These findings establish that CD95 is a critical regulator of effector T cell homeostasis in chronic immune activation...
  11. ncbi request reprint Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy
    Erwan Piriou
    Department of Clinical Viro Immunology, Sanquin Research at CLB and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    J Immunol 175:2010-7. 2005
    ..In conclusion, long-term HAART does not alter the EBV DNA load, but does lead to a restoration of EBNA1-specific T cell responses, which might allow better control of EBV-infected cells when applied early enough during HIV infection...
  12. ncbi request reprint Detailed kinetics of EBV-specific CD4+ and CD8+ T cells during primary EBV infection in a kidney transplant patient
    Erwan R W A N Piriou
    Department of Clinical Viro Immunology, Sanquin Research at CLB, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Immunol 119:16-20. 2006
    ....
  13. doi request reprint Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia
    Margot Jak
    Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Leuk Lymphoma 50:788-801. 2009
    ..In conclusion, T(reg) cells in CLL may accumulate both by increased formation, facilitated by CD27-CD70 interaction in the lymph node proliferation centres, and decreased sensitivity to apoptosis because of a shifted Noxa-Bcl-2 balance...
  14. ncbi request reprint CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development
    Michiel F van Oosterwijk
    Department of Experimental Immunology, Academic Medical Centre, Amsterdam, The Netherlands
    Int Immunol 19:713-8. 2007
    ..Thus, CD27-CD70 interactions may promote Th1 formation by permitting naive T cells to respond to differentiation signals and by promoting survival of activated effector T cells...
  15. ncbi request reprint Signaling through CD70 regulates B cell activation and IgG production
    Ramon Arens
    Department of Hematology, Academic Medical Center, University of Amsterdam, The Netherlands
    J Immunol 173:3901-8. 2004
    ..Together, the in vitro and in vivo data demonstrate that CD70 has potent reverse signaling properties in B cells, initiating a signaling cascade that regulates expansion and differentiation...
  16. ncbi request reprint Immune activation modulates hematopoiesis through interactions between CD27 and CD70
    Martijn A Nolte
    Department of Hematology, F4 224, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ, Amsterdam, The Netherlands
    Nat Immunol 6:412-8. 2005
    ..As CD70 is expressed only on activated immune cells, we suggest that CD27 triggering on early progenitor cells provides a negative feedback signal to leukocyte differentiation during immune activation...
  17. ncbi request reprint c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
    Delfine Y H Hallaert
    Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Blood 112:5141-9. 2008
    ..These data indicate that CLL cells in chemoresistant niches may be sensitive to therapeutic strategies that include c-Abl inhibitors...
  18. doi request reprint High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients
    Mars B van 't Veer
    Department of Haematology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Br J Haematol 144:524-30. 2009
    ..In conclusion, high-dose Ara-C and BEAM with stem cell rescue in newly diagnosed MCL patients responsive to R-CHOP is a manageable treatment with respect to toxicity. This regimen leads to long-term, but probably not durable, remissions...
  19. ncbi request reprint CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack
    Arnon P Kater
    Department of Haematology, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
    Br J Haematol 127:404-15. 2004
    ..These data support therapeutic exploitation of CD40 stimulation in B-CLL, provided that a strong CTL component is induced...
  20. ncbi request reprint B cells are crucial for both development and maintenance of the splenic marginal zone
    Martijn A Nolte
    Department of Molecular Cell Biology, Vrije Universiteit Medical Center, Academic Medical Center, Amsterdam, The Netherlands
    J Immunol 172:3620-7. 2004
    ..This direct correlation between circulating B cells and the function of the spleen implies an increased risk for B cell lymphopenic patients with bacterial infections...
  21. ncbi request reprint Autologous cytomegalovirus-specific T cells as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia
    Arnon P Kater
    Department of Haematology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
    Br J Haematol 126:512-6. 2004
    ..Directing virus-specific T cells to B-CLL may overcome the inadequate immunostimulatory capacity of these cells, which could be exploited for T-cell mediated immunotherapy...
  22. doi request reprint Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection
    Erwan Piriou
    Department of Clinical Viro Immunology, Sanquin Research at CLB and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Infect Dis 46:313-6. 2008
    ..Immune activation may contribute to the increase in this setpoint after human immunodeficiency virus seroconversion...
  23. doi request reprint Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison
    Jan J Cornelissen
    Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
    Blood 113:1375-82. 2009
    ..This trial is registered with http://www.trialregister.nl under trial ID NTR228...
  24. doi request reprint Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program
    Evelien Kneppers
    Department of Haematology, University Medical Center, Utrecht, The Netherlands
    Clin Lymphoma Myeloma Leuk 10:138-43. 2010
    ..A median of 3 previous lines of therapy were given, including thalidomide in 91%. Most patients were treated until progression or intolerable toxicity...
  25. ncbi request reprint Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial
    Edo Vellenga
    Department of Hematology, University Medical Center, Groningen, The Netherlands
    Blood 111:537-43. 2008
    ..These results demonstrate improved FFS and PFS for relapsed aggressive B-cell NHL if rituximab is added to the re-induction chemotherapy regimen...
  26. doi request reprint Dasatinib in combination with fludarabine in patients with refractory chronic lymphocytic leukemia: a multicenter phase 2 study
    Arnon P Kater
    Department of Hematology, Academic Medical Centre, Amsterdam, The Netherlands LYMMCARE Lymphoma and Myeloma Center Amsterdam, The Netherlands Electronic address
    Leuk Res 38:34-41. 2014
    ..In conclusion, dasatinib/fludarabine combination has modest clinical efficacy in fludarabine-refractory patients...
  27. doi request reprint Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia
    Jacqueline M Tromp
    Departments of Hematology and Experimental Immunology, and Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Clin Cancer Res 18:487-98. 2012
    ..We aimed to define which antiapoptotic proteins determine resistance to ABT-737 in CLL and whether combination of known antileukemia drugs and ABT-737 was able to induce apoptosis of CD40-stimulated CLL cells...
  28. ncbi request reprint Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma
    Erwan Piriou
    Department of Clinical Viro Immunology, Sanquin Research at CLB and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, The Netherlands
    Blood 106:3166-74. 2005
    ..Interestingly, BZLF1-specific T cells were not lost in all progressors to NHL, suggesting a different function of these cells in the surveillance of EBV-infected B cells...
  29. doi request reprint Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
    Henk M Lokhorst
    Department of Hematology, University Medical Center, Utrecht, The Netherlands
    Haematologica 93:124-7. 2008
    ..However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms...
  30. doi request reprint No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia
    Sanne H Tonino
    Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Blood 112:840-3. 2008
    ..In conclusion, our data do not support an important contribution of CD38 triggering by CD31 to the proliferative and antiapoptotic state of the leukemic clone...
  31. ncbi request reprint CD27 contributes to the early systemic immune response to Mycobacterium tuberculosis infection but does not affect outcome
    Catharina W Wieland
    Center of Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Int Immunol 18:1531-9. 2006
    ..Our data suggest that CD27 does not contribute to the local IFNgamma-mediated response and long-term protection against M. tuberculosis...
  32. ncbi request reprint Apoptosis via the B cell antigen receptor requires Bax translocation and involves mitochondrial depolarization, cytochrome C release, and caspase-9 activation
    Eric Eldering
    Department of Experimental Immunology, Academical Medical Centre, Amsterdam, The Netherlands
    Eur J Immunol 34:1950-60. 2004
    ..Instead, our data show for the first time that the BCR-signal causes Bax translocation, followed by mitochondrial depolarization, and cytC release. Subsequent caspase-9 activation can solely account for events further downstream...
  33. doi request reprint CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
    Margot Jak
    Department of Hematology, Academic Medical Centre, Amsterdam, The Netherlands
    Blood 118:5178-88. 2011
    ..Our findings indicate that GA101 has efficacy against chemoresistant CLL, and provide a rationale for combining cytotoxic drugs with anti-CD20 mAbs...
  34. ncbi request reprint Expansion of CMV-specific CD8+CD45RA+CD27- T cells in B-cell chronic lymphocytic leukemia
    Wendelina J M Mackus
    Department of Hematology, Academic Medical Center, Rm F4 210, University of Amsterdam, PO Box 22660, 1100 DD Amsterdam, The Netherlands
    Blood 102:1057-63. 2003
    ..Furthermore, because in CMV-seronegative patients no increase in cytotoxic CD8+ T cells is found, our studies do not support the hypothesis that tumor-specific T cells account for T-cell expansion in B-CLL...
  35. ncbi request reprint The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
    Henk M Lokhorst
    University Medical Center Utrecht, Department of Haematology, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
    Blood 103:4362-4. 2004
    ....
  36. ncbi request reprint Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity
    Laura A Smit
    Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
    Blood 109:1660-8. 2007
    ..These data indicate that suppression of Noxa in the lymph node environment contributes to the persistence of B-CLL at these sites and suggest that therapeutic targeting of Noxa might be beneficial...
  37. ncbi request reprint Cellular immune therapy for chronic lymphocytic leukemia
    Arnon P Kater
    Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Blood 110:2811-8. 2007
    ..We will discuss the different strategies being developed to overcome these limitations that might provide for effective cellular immune therapy of CLL...
  38. ncbi request reprint Lethal T cell immunodeficiency induced by chronic costimulation via CD27-CD70 interactions
    Kiki Tesselaar
    Laboratory for Experimental Immunology, Academic Medical Center, P O Box 22700, 1100DD Amsterdam, The Netherlands
    Nat Immunol 4:49-54. 2003
    ..Thus, persistent delivery of costimulatory signals via CD27-CD70 interactions, as may occur during chronic active viral infections, can exhaust the T cell pool and is sufficient to induce lethal immunodeficiency...
  39. pmc Illegitimate WNT signaling promotes proliferation of multiple myeloma cells
    Patrick W B Derksen
    Department of Pathology, Academic Medical Center, University of Amsterdam, 1105AZ, Amsterdam, The Netherlands
    Proc Natl Acad Sci U S A 101:6122-7. 2004
    ..We therefore suggest that MM cells are dependent on an active WNT signal, which may have important implications for the management of this incurable form of cancer...
  40. ncbi request reprint Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM
    Henk M Lokhorst
    Department of Hematology, University Medical Center Utrecht, HP G03 647, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands
    J Clin Oncol 21:1728-33. 2003
    ..To determine in a prospective study the efficacy, toxicity, and long-term outcome of up-front allogeneic stem-cell transplantation (allo-SCT) in multiple myeloma (MM)...
  41. ncbi request reprint Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma
    Debbie van Baarle
    Department of Clinical Viro Immunology, Sanquin Research at CLB, and Department of Hematology, Academic Medical Center, University of Amsterdam, 1066 CX Amsterdam, The Netherlands
    J Infect Dis 186:405-9. 2002
    ..EBV DNA was also detectable in serum at some time points but at a lower level...
  42. ncbi request reprint Rituximab treatment results in impaired secondary humoral immune responsiveness
    Lizet E van der Kolk
    Department of Hematology, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Blood 100:2257-9. 2002
    ..These findings are relevant regarding the feasibility of rituximab in maintenance treatment and may also offer a rationale for the treatment of antibody-mediated autoimmune diseases with rituximab...
  43. doi request reprint The practice of reporting transfusion-related acute lung injury: a national survey among clinical and preclinical disciplines
    Alexander P J Vlaar
    Department of Intensive Care Medicine and Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands
    Transfusion 50:443-51. 2010
    ..g., sepsis) predisposes to TRALI. TRALI is a clinical diagnosis. Disciplines involved in managing TRALI may differ in decision-making on the reporting of TRALI...
  44. ncbi request reprint Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells
    Stefan Kostense
    Department of Clinical Viro Immunology, CLB and Laboratory for Experimental and Clinical Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Eur J Immunol 32:1080-9. 2002
    ..Overall, these data indicate that HAART improves the antigen responsiveness of both HIV- and EBV-specific T cells, which is associated with an increase in CD4(+) T cells...
  45. ncbi request reprint Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study
    Christine M Segeren
    Erasmus Medical Center Rotterdam, The Netherlands
    Blood 101:2144-51. 2003
    ..However, it did not result in a better EFS and OS...
  46. pmc Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation
    Ramon Arens
    Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Netherlands
    J Exp Med 199:1595-605. 2004
    ..Thus, CD70 costimulation enhances both the expansion and per cell activity of antigen-specific CD8+ T cells...
  47. ncbi request reprint Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection
    Debbie van Baarle
    Department of Clinical Viro Immunology, CLB Sanquin and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, The Netherlands
    AIDS 16:2001-11. 2002
    ..To investigate the underlying mechanism of this loss of immune control phenotypic analysis of HIV- and Epstein-Barr virus (EBV)-specific CD8+ T cells was performed...
  48. ncbi request reprint Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue
    Debbie van Baarle
    Dept of Clinical Viro Immunology, Sanquin Research at CLB and Landsteiner Laboratory of the Academic Medical Center, University of Amsterdam, The Netherlands
    Trends Immunol 23:586-91. 2002
    ..We postulate that CD27(-) effector CD8(+) T cells might be required for adequate control of chronic viral infection and prevention of disease development...
  49. ncbi request reprint Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
    Pieter Sonneveld
    Erasmus Medical Center Rotterdam, The Netherlands
    Haematologica 92:928-35. 2007
    ..The Dutch-Belgian HOVON group performed a randomized phase 3 trial to compare single non-myeloablative intensive treatment with double, intensive treatment in previously untreated patients with multiple myeloma (MM)...
  50. ncbi request reprint Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
    Bertrand Coiffier
    Departement d Hematologie, Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France
    Blood 111:1094-100. 2008
    ..Preliminary data on safety and objective response are encouraging and support further studies on the role of ofatumumab in CLL patients. This trial was registered at www.clinicaltrials.gov as no. NCT00093314...
  51. ncbi request reprint Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma
    Niels W C J van de Donk
    Blood 107:3415-6. 2006